Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Alemtuzumab 24 mg vs interferon beta‐1a

Leaving the study early · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower dropouts compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab for multiple sclerosis 2023 · Cochrane Headline outcomes only
RR 0.08 [0.01, 0.57]
1 study · 215 participants
Low

Alemtuzumab 12 mg vs interferon beta‐1a

Dropout · adults with relapsing–remitting multiple sclerosis

It is very uncertain whether alemtuzumab 12 mg changes dropouts Assessed by: number of participants who dropped out compared with interferon beta‐1a (very low certainty).

1 finding from 1 review

Alemtuzumab for multiple sclerosis 2023 · Cochrane Headline outcomes only
RR 0.81 [0.57, 1.14]
1 study · 224 participants
Very low